Appeal Filed to Overturn Xarelto Bellwether Losses
Earlier this year, there were multiple Xarelto bellwether trials. Unfortunately, a jury ruled in favor the defense. Now, two plaintiffs who lost the trials filed appeals, because they do not feel they received a fair trial.
Approved by the FDA in 2011, Xarelto is used to reduce the risk of deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots. Manufacturers Bayer and Janssen promoted the drug has the gold standard for anticoagulants. However, it may be more dangerous than other medications on the market since there is no antidote.
The drug is also dangerous because the once-a-day dosing can be difficult, and it can complicate the healing of wounds. There is a tiny window of time between a safe Xarelto dose and a dangerous one. Overdose or not enough of the medication is a grim reality. Plus, doctors do not need to monitor their patients regularly unlike the previous widely used blood thinner, warfarin. This leaves problems to grow, and doctors can’t treat them in a timely manner.
Previously, there have been multiple bellwether trials in a large Xarelto litigation. Joseph Boudreaux and Joseph Orr were the first plaintiffs to go to trial in the U.S. District Court, Eastern District of Louisiana. Both claimed Xarelto caused their life-threatening internal bleeding. They insisted that Bayer and Janssen Pharmaceuticals failed to provide doctors and patients with adequate warnings about Xarelto’s side effects.
In both cases, the jury ruled for the pharmaceutical companies. Afterward, U.S. District Judge Eldon E. Fallon denied both plaintiffs new trials in September.
Both men described nine court decisions dating back to April for the appeals court to consider. This includes their appeal for new trials. They also state the judge denied their request to exclude opinions and speculative testimony from the drug companies’ expert.
Both drug companies have won three bellwether trials thus far. However, a fourth trial is still pending, and overall anything can happen. There are also nearly 20,000 cases in the U.S. District Court, Eastern District of Louisiana. Plaintiffs feel the manufacturers marketed Xarelto irresponsibly, especially since there is not an antidote. Plus, regular monitoring could help Xarelto patients, yet it isn’t required like warfarin.
If Xarelto Harmed You
Thousands of patients are speaking out against Xarelto. They decided to take a stand and ask for compensation from the manufacturers Bayer and Janssen. They feel these companies are profiting from their pains and their loved ones’ deaths. The drug is dangerous because the administration can be difficult, and it can complicate the healing of wounds. There is a tiny window of time between a safe Xarelto dose and a dangerous one. Overdose or not enough of the medication is a grim reality.
Xarelto lawsuits are similar to lawsuits over Pradaxa, another newer-generation anticoagulant. Michael Brady Lynch, the founder of The Michael Brady Lynch Firm is leading the country in Pradaxa lawsuits. Michael was a member of the Plaintiff’s Steering Committee in the Pradaxa Multi-District Litigation and was instrumental in securing the $650 million settlement for those injured by Pradaxa’s uncontrollable bleeding. Mr. Lynch continues to be a leader in Pradaxa litigation nationwide in representing those who continue to suffer uncontrollable bleeding events from Pradaxa.
Therefore, if the conduct of a drug company in manufacturing and selling drug is found to be highly reckless, punitive damages may be awarded to punish the company and deter similar conduct in the future. If you had a bleeding event after taking Xarelto, please speak to us to learn more about your rights.
Furthermore, case evaluations are free of cost and without obligation. Call us today at (877) 513-9517 or contact us online to speak with an attorney about your options. We may be able to get you the help you need.